FDA
-
-
-
-
-
-
-
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europ
-
-
-
-
-
-
-
Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

